Reprint

Epithelial-Mesenchymal Plasticity in Cancer Metastasis

Molecular Reprogramming, Cellular Adaptation, and Clinical Implications

Edited by
August 2020
512 pages
  • ISBN978-3-03936-724-5 (Hardback)
  • ISBN978-3-03936-725-2 (PDF)

This book is a reprint of the Special Issue Epithelial-Mesenchymal Plasticity in Cancer Metastasis: Molecular Reprogramming, Cellular Adaptation, and Clinical Implications that was published in

Medicine & Pharmacology
Public Health & Healthcare
Summary

Recent studies have highlighted that epithelial-mesenchymal transition (EMT) is not only about cell migration and invasion, but it can also govern many other important elements such as immunosuppression, metabolic reprogramming, senescence-associated secretory phenotype (SASP), stem cell properties, therapy resistance, and tumor microenvironment interactions. With the on-going debate about the requirement of EMT for cancer metastasis, an emerging focus on intermediate states of EMT and its reverse process mesenchymal-epithelial transition (MET) offer new ideas for metastatic requirements and the dynamics of EMT/MET during the entire metastatic cascade. Therefore, we would like to initiate discussions on viewing EMT and its downstream signaling networks as a fulcrum of cellular plasticity, and a facilitator of the adaptive responses of cancer cells to distant organ microenvironments and various therapeutic assaults. We hereby invite scientists who have prominently contributed to this field, and whose valuable insights have led to the appreciation of epithelial-mesenchymal plasticity as a more comprehensive mediator of the adaptive response of cancer cells, with huge implications in metastasis, drug resistance, tumor relapse, and patient survival.

Format
  • Hardback
License
© 2020 by the authors; CC BY-NC-ND license
Keywords
tumor niche; Epithelial–Mesenchymal plasticity; cancer-derived exosomes; extracellular vesicles; metastasis; evolution; systems biology; autophagy; lung cancer; epithelial–mesenchymal transition; tumor invasiveness; metabolism; high-grade serous ovarian carcinoma; epithelial-to-mesenchymal transition; molecular stratification; biomarkers; scoring system; immunohistochemistry; endometrial cancer; epithelial-mesenchymal transition; AKT/PI3K; Ras/Raf/MEK/ERK; WNT/β-catenin; epithelial-mesenchymal transition; endoplasmic reticulum stress; metastasis; plasticity; unfolded protein response; breast cancer; subtypes; EMT; TWIST; MMPs; immune cells; TME; therapy resistance; metastasis; epithelial-to-mesenchymal transition; collective invasion; heterogeneity; hybrid; epithelial–mesenchymal transition; hybrid E/M states; plasticity; tumour heterogeneity; treatment resistance; immunotherapy scape; urothelial cancer; phosphoproteomics; activated pathways; ingenuity pathway analysis; molecular subtypes; epithelial–mesenchymal transition; EMT spectrum; hybrid epithelial/mesenchymal phenotypes; CTC clusters; stemness; immune suppression; EMT metrics; systems biology; organotropism metastasis; EMT heterogeneity; tumor immune escape; cell–cell communication; Snail1; transcriptional factor; Epithelial to mesenchymal transition (EMT); tumor invasion; drug resistance; SNA1; metabolomics; glucose metabolism; tumor metabolism; epithelial-mesenchymal transition; pancreatic adenocarcinoma; copy number variations (CNV); epithelial-mesenchymal transition (EMT); intratumoral heterogeneity; mesenchymal-epithelial transition (MET); phenotypic plasticity; single cell-derived clones; whole exome sequencing; epithelial to mesenchymal transition; morphology; phenotypic state transition; quantitative imaging; mathematical modeling; ultrasensitive switch; quasi-potential landscape; metastasis; functional read-outs; metastatic modalities; live cell imaging; quantitative metrics; epithelial-mesenchymal transition; metabolism; plasticity; epigenetics; drug resistance; ATP5E; AMPK; EMT; Metastasis; Colorectal Cancer; cancer; invasion; invasive front; epithelial–mesenchymal transition; heterogeneity; metastasis; constricted microchannel; hydrodynamic parameters; breast cancer cells; epithelial to mesenchymal transition; EMT; mesenchymal to epithelial transition; MET; cell viability; copy number variations (CNV); epithelial–mesenchymal transition (EMT); karyotyping; mesenchymal–epithelial transition (MET); metabolism; proteomics; RNA-sequencing; seahorse extracellular flux analyser; whole exome sequencing; circulating tumor cells (CTCs); breast cancer; 3D culture; epithelial-mesenchymal heterogeneity; cellular dynamics; epithelial-to-mesenchymal transition; cell plasticity; cancer stem cells; mathematical modeling; population homeostasis; dermatan sulfate; breast cancer; iduronate-2-sulfatase; colorectal adenoma; colorectal carcinoma; metastases; intra-tumour heterogeneity; epithelial-mesenchymal transition; miR-200 family; target genes; n/a